Top Markets
Coin of the day
AcelRx Pharmaceuticals, Inc. AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc.

ACRX
株式のランク #31918
AcelRx Pharmaceuticals, Inc. is a specialized biopharmaceutical firm primarily... AcelRx Pharmaceuticals, Inc. is a specialized biopharmaceutical firm primarily dedicated to advancing and bringing to market medical solutions for managing acute pain. The company's key commercial products include DSUVIA and DZUVEO, which are 30 microgram sufentanil tablets administered under the tongue, intended for treating significant short-term pain. AcelRx also develops ZALVISO, a pre-programmed, patient-managed analgesia system that enables hospital patients experiencing moderate-to-severe acute pain to self-administer sufentanil sublingual tablets for their pain relief. In its development pipeline, AcelRx is progressing ARX-02, which is currently in Phase 2 clinical trials, targeting sudden, intense cancer-related pain in individuals who are tolerant to opioid medications. Another candidate, 4ARX-03, is being investigated for its utility in providing mild sedation and pain relief during various medical procedures that might cause discomfort. Beyond acute pain, AcelRx's investigational portfolio features Niyad, a regional anticoagulant designed for use in external blood circulation systems. Furthermore, LTX-608, a nafamostat formulation for direct intravenous infusion, is being explored as an experimental treatment for a range of conditions, including COVID, severe lung injury (acute respiratory distress syndrome), widespread blood clotting (disseminated intravascular coagulation), and acute pancreatitis. The company was founded in 2005 and initially operated under the name SuRx, Inc., before officially rebranding as AcelRx Pharmaceuticals, Inc. in August 2006. It is headquartered in Hayward, California.
株価
$0.922
最終同期: 2024-02-05
時価総額
$11.68M
変化(1日)
-1.91%
変化(1年)
0.00%
US
取引 AcelRx Pharmaceuticals, Inc. (ACRX)

カテゴリー

AcelRx Pharmaceuticals, Inc.(ACRX)の配当利回りの履歴
AcelRx Pharmaceuticals, Inc.(銘柄コード: ACRX)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
AcelRx Pharmaceuticals, Inc.(ACRX)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)